Ren Yanqiao, Dong Xiangjun, Chen Lei, Sun Tao, Alwalid Osamah, Kan Xuefeng, Su Yangbo, Xiong Bin, Liang Huimin, Zheng Chuansheng, Han Ping
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hubei Key Laboratory of Molecular Imaging, Wuhan, China.
Front Oncol. 2021 Mar 2;11:582544. doi: 10.3389/fonc.2021.582544. eCollection 2021.
The purpose of this study was to evaluate the efficacy and safety of iodine-125 (I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolization (TACE).
This retrospective study analyzed the consecutive medical records of 31 HCC patients with residual tumors located at complex sites (such as large blood vessels, gallbladder, diaphragm dome, etc.) after TACE from May 2014 to December 2018, all of whom received I seeds implantation therapy. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were documented.
A total of 607 seeds were implanted in 31 patients, with an average of 19.6±10.4 (range, 8-48) seeds per patient. Median OS and PFS were 33 months (95% CI: 27.1 months, 38.9 months) and 15 months (95% CI: 9.6 months, 20.4 months), respectively. Although univariate analysis showed that albumin, prothrombin time, alpha-fetoprotein level, Child-Pugh score, and lipiodol deposition in tumor were associated with OS, multivariate analysis showed that none of them was an independent prognostic factor for OS. Multivariate analysis showed that prothrombin time was an independent prognostic factor for PFS. No operation-related deaths in this study. Although pneumothorax was present in two patients and subcutaneous abscess in one patient, symptoms improved in all three patients with appropriate treatment. Common minor complications included fever, abdominal pain and leukopenia and no grade≥3 adverse events were observed.
I seeds implantation under the combined guidance of ultrasound and CT is safe and effective for patients with residual HCC located at complex sites after TACE. This is a promising treatment approach and deserves further discussion.
本研究旨在评估在超声和计算机断层扫描(CT)引导下,碘-125(I)粒子植入治疗经动脉化疗栓塞术(TACE)后位于复杂部位的残留肝细胞癌(HCC)的疗效和安全性。
本回顾性研究分析了2014年5月至2018年12月期间31例TACE术后残留肿瘤位于复杂部位(如大血管、胆囊、膈顶等)的HCC患者的连续病历,所有患者均接受了I粒子植入治疗。记录总生存期(OS)、无进展生存期(PFS)、复发情况及并发症。
31例患者共植入607枚粒子,平均每例患者植入19.6±10.4(范围8 - 48)枚。OS和PFS的中位数分别为33个月(95%CI:27.1个月,38.9个月)和15个月(95%CI:9.6个月,20.4个月)。单因素分析显示白蛋白、凝血酶原时间、甲胎蛋白水平、Child-Pugh评分及肿瘤内碘油沉积与OS相关,但多因素分析显示它们均不是OS的独立预后因素。多因素分析显示凝血酶原时间是PFS的独立预后因素。本研究无手术相关死亡病例。虽然有2例患者出现气胸,1例患者出现皮下脓肿,但经适当治疗后,3例患者症状均有改善。常见的轻微并发症包括发热、腹痛和白细胞减少,未观察到≥3级不良事件。
超声和CT联合引导下I粒子植入治疗TACE术后位于复杂部位的残留HCC患者安全有效。这是一种有前景的治疗方法,值得进一步探讨。